2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow BRCA 2 Gene Mutation: new trials by email Literature Review of BRCA 2 Gene Mutation trials Research Report on BRCA 2 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. Olaparib, Physician's choice chemotherapy - Breast Cancer Metastatic, BRCA 1 Gene Mutation | Phase 3 | Completed | AstraZeneca | 302 | 2014-03-27 | 2026-02-13 |
| A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) talazoparib, Physician's-Choice - Breast Neoplasms, BRCA 1 Gene Mutation | Phase 3 | Completed | Pfizer | 431 | 2013-10-14 | 2022-01-20 |
Breast Neoplasms (2) · Neoplasm Metastasis (1)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
olaparib (1) · talazoparib (1)
AstraZeneca (1) · Pfizer (1)
France (2) · Italy (2) · Poland (2) · Russia (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · United States (2) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · China (1) · Czechia (1)
Mark Robson, MD (1)